Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.
Lee
Byoung Hwan
BH
Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
Kim
Nayoung
N
Hwang
Tae Jun
TJ
Lee
Sang Hyub
SH
Park
Young Soo
YS
Hwang
Jin-Hyeok
JH
Kim
Jin-Wook
JW
Jeong
Sook-Hyang
SH
Lee
Dong Hoo
DH
Jung
Hyun Chae
HC
Song
In Sung
IS
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D001729:Bismuth / Q000008:administration & dosage*; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D064098:Esomeprazole / Q000008:administration & dosage; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage; D008875:Middle Aged; D011446:Prospective Studies; D056910:Republic of Korea; D013752:Tetracycline / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D008795:Metronidazole; D013752:Tetracycline; D064098:Esomeprazole; D001729:Bismuth